GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (LTS:0P3C) » Definitions » Shiller PE Ratio

Karolinska Development AB (LTS:0P3C) Shiller PE Ratio : (As of Sep. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Karolinska Development AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Karolinska Development AB Shiller PE Ratio Historical Data

The historical data trend for Karolinska Development AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Shiller PE Ratio Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Karolinska Development AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Karolinska Development AB's Shiller PE Ratio

For the Biotechnology subindustry, Karolinska Development AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Shiller PE Ratio falls into.



Karolinska Development AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Karolinska Development AB's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, Karolinska Development AB's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.06/132.7160*132.7160
=-0.060

Current CPI (Jun. 2024) = 132.7160.

Karolinska Development AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 -2.187 100.161 -2.898
201412 -0.815 100.225 -1.079
201503 -4.180 99.950 -5.550
201506 -10.910 99.995 -14.480
201509 -0.460 100.228 -0.609
201512 -2.019 100.276 -2.672
201603 -1.665 100.751 -2.193
201606 -1.266 101.019 -1.663
201609 -0.301 101.138 -0.395
201612 -0.390 102.022 -0.507
201703 -0.416 102.022 -0.541
201706 -0.301 102.752 -0.389
201709 2.683 103.279 3.448
201712 0.425 103.793 0.543
201803 -0.275 103.962 -0.351
201806 0.434 104.875 0.549
201809 0.053 105.679 0.067
201812 0.213 105.912 0.267
201903 -0.257 105.886 -0.322
201906 0.106 106.742 0.132
201909 -0.204 107.214 -0.253
201912 3.985 107.766 4.908
202003 -0.638 106.563 -0.795
202006 0.009 107.498 0.011
202009 -0.859 107.635 -1.059
202012 0.434 108.296 0.532
202103 -0.140 108.360 -0.171
202106 1.230 108.928 1.499
202109 -0.010 110.338 -0.012
202112 -0.110 112.486 -0.130
202203 -0.130 114.825 -0.150
202206 -0.080 118.384 -0.090
202209 -0.170 122.296 -0.184
202212 0.050 126.365 0.053
202303 -0.100 127.042 -0.104
202306 0.090 129.407 0.092
202309 0.040 130.224 0.041
202312 -0.010 131.912 -0.010
202403 0.001 132.205 0.001
202406 -0.060 132.716 -0.060

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Karolinska Development AB  (LTS:0P3C) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Karolinska Development AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.

Karolinska Development AB Headlines

No Headlines